GLP‑1 weight-loss plateau: why it happens and what to do

Introduction

A weight-loss stall on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) deserves a review of your trend and health goals. Your body needs fewer calories after weight loss, which can make further loss harder. 1 A stable weight alone does not mean your medicine has stopped working or tell you what to change.

Understand what researchers mean by a plateau

Compare readings taken under similar conditions over several weeks rather than drawing conclusions from two weigh-ins. Note changes in bowel habits, food intake, and symptoms alongside the dates. Bring the record to your clinician if the trend concerns you; there is no required waiting period before asking for help.

In 2025, researchers took another look at data from SURMOUNT-1 and SURMOUNT-4. They defined a plateau as less than 5% weight change over a 12-week period and each later 12-week period. They started measuring these periods at week 24. Their definition allowed continued weight loss. 2

The SURMOUNT-1 analysis included 1,438 adults with overweight or obesity and no diabetes. Researchers selected people who had taken at least 75% of their doses and lost at least 5% of their starting weight. They also had to reach their assigned dose by week 24, keep that dose, and have a weight measurement at week 72. About 88% to 90% across body mass index (BMI) groups met the plateau definition by week 72. These results cannot predict when every patient will plateau. 2

Review nutrition and activity without crash dieting

Weight maintenance still takes work. NIDDK notes that metabolism slows during weight loss and that hormonal changes can make maintaining a lower weight difficult. Review your plan with your care team as your weight changes; do not assume you need to eat less. 1

Prepare a short review for your next appointment:

• Eating pattern: Record several typical days, including drinks and snacks. Note missed meals as well as extra meals or snacks.
• Protein and strength: Ask whether your meals and exercise meet your needs. Let them know if you’re experiencing any muscle weakness.
• Practical barriers: Describe symptoms, food costs, time constraints, or treatment access problems that make the plan hard to follow.

The 2025 joint nutrition advisory, corrected in 2026, recommends individualized nutrition and strength training to support muscle during weight loss. 3 Our protein guide can help you prepare questions.

CDC recommends muscle-strengthening activity on at least two days weekly for adults. Choose activity you can manage. This general advice does not guarantee that weight loss will restart. 4 See the exercise guide for starting options.

Discuss treatment options in context

Tell your prescriber how long the trend has been stable and whether hunger, side effects, or other medicines have changed. Do not change doses or switch medicines on your own.

In SURMOUNT-5, 751 adults with obesity without type 2 diabetes took the highest dose they could tolerate within the study’s options: weekly tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg. At 72 weeks, estimated average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide. This head-to-head trial did not test switching after a plateau, so it cannot establish that switching will restart weight loss or provide a timeline. 5

The switching guide covers questions for a prescriber-led discussion. No food, exercise routine, or medication switch guarantees further loss.

Track your plateau with Shotsy

Use Shotsy to keep weight readings, injection history, and nutrition notes together. Shotsy provides a PDF export of charts that contain all of this information that you can bring to your appointment or send to your provider.

Conclusion

Review your longer-term trend and whether your current plan supports eating, activity, and daily function. Work with your care team on realistic next steps, including whether maintaining your weight is a useful treatment outcome.